Impact of renin-angiotensin system inhibitors on long-term clinical outcomes of patients with rheumatic heart disease.

Renin-angiotensin-aldosterone system inhibitor treatment was significantly associated with decreased risks of mortality, HF rehospitalization, and new-onset AF in RHD patients in median 5.9 year follow-up.